• SPX
  • $5,782.96
  • 0.55 %
  • $31.83
  • DJI
  • $42,425.10
  • 0.82 %
  • $344.72
  • N225
  • $39,277.96
  • 0.87 %
  • $340.42
  • FTSE
  • $8,243.92
  • 0.65 %
  • $53.31
  • IXIC
  • $18,254.27
  • 0.39 %
  • $71.35
Cyclacel Pharmaceuticals, Inc. (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals, Inc. (CYCC) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.85

-$0.04

(-4.01%)

Day's range
$0.85
Day's range
$0.94
50-day range
$0.8499
Day's range
$1.76
  • Country: US
  • ISIN: US23254L8019
52 wk range
$0.85
Day's range
$11.4
  • CEO: Mr. Spiro George Rombotis
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -83.88
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (CYCC)
  • Company Cyclacel Pharmaceuticals, Inc.
  • Price $0.85
  • Changes Percentage (-4.01%)
  • Change -$0.04
  • Day Low $0.85
  • Day High $0.94
  • Year High $11.40

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

  • Last Earnings 06/09/2016
  • Ex-Dividend for 5/16 Dividend 07/13/2016
  • Dividend Payable 08/01/2016
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$22.02
  • Trailing P/E Ratio -0.09
  • Forward P/E Ratio -0.09
  • P/E Growth -0.09
  • Net Income $-22,555,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.